Main Conference - Day 3 (May 14)Thursday, 14 May 2026

RNAi is well-positioned to positively impact the lives of patients living with obesity and related metabolic disorders, due to its strong clinical track record of safety, efficacy and durability. As a modality, mRNA silencing enables pharmacological intervention in diverse disease-associated mechanisms including thermogenesis, lipogenesis, energy expenditure and inflammation. SanegeneBio is developing differentiated tissue-selective delivery technologies using our LEAD (Ligand and Enhancer Assisted Delivery) platform. In this presentation, we will share Phase 1 clinical data demonstrating potential for best-in-class siRNA payloads, our novel ligand-based approach targeting adipocytes and skeletal muscle, and preclinical proof-of-concept for several obesity targets. Together, these data support the promise of RNAi-based medicines as a transformative modality in the treatment of obesity—capable of addressing limitations of existing therapies and establishing a new standard of care.